AstraZeneca Inks R&D Deal With Ramaswamy's Roivant for Hush-Hush Indication Post author:Sam Post published:October 18, 2017 Post category:BioPharma Vivek Ramaswamy’s parent company, Roivant Sciences, inked a development deal with Astra. Source: BioSpace You Might Also Like Former GlaxoSmithKline CEO and R&D Boss Secure New Gigs at Biotech VC Firms September 18, 2017 Catalyst Biosciences To Present At 19th Annual BIO CEO & Investor Conference February 2, 2017 Egalet Reports First Quarter 2017 Financial Results May 9, 2017
